Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

679 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study.
Fletcher K, Cortellini A, Ganta T, Kankaria R, Song H, Ye F, Irlmeier R, Debnath N, Saeed A, Radford M, Alahmadi A, Diamond A, Hoimes C, Presley CJ, Owen DH, Abou Alaiwi S, Nassar AH, Lamberti G, Perrone F, Buti S, Giusti R, Filetti M, Vanella V, Mallardo D, Sussman TA, Galetta D, Kalofonou F, Daniels E, Ascierto PA, Pinato DJ, Nebhan C, Berg S, Choueiri TK, Marron TU, Wang Y, Naqash AR, Johnson DB. Fletcher K, et al. Among authors: johnson db. Cancer Lett. 2024 Aug 1;596:217001. doi: 10.1016/j.canlet.2024.217001. Epub 2024 Jun 3. Cancer Lett. 2024. PMID: 38838764 Free article.
Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center.
Johnson DB, Friedman DL, Berry E, Decker I, Ye F, Zhao S, Morgans AK, Puzanov I, Sosman JA, Lovly CM. Johnson DB, et al. Cancer Immunol Res. 2015 May;3(5):464-9. doi: 10.1158/2326-6066.CIR-14-0217. Epub 2015 Feb 3. Cancer Immunol Res. 2015. PMID: 25649350 Free PMC article. Clinical Trial.
The efficacy of anti-PD-1 agents in acral and mucosal melanoma.
Shoushtari AN, Munhoz RR, Kuk D, Ott PA, Johnson DB, Tsai KK, Rapisuwon S, Eroglu Z, Sullivan RJ, Luke JJ, Gangadhar TC, Salama AK, Clark V, Burias C, Puzanov I, Atkins MB, Algazi AP, Ribas A, Wolchok JD, Postow MA. Shoushtari AN, et al. Among authors: johnson db. Cancer. 2016 Nov 15;122(21):3354-3362. doi: 10.1002/cncr.30259. Epub 2016 Aug 17. Cancer. 2016. PMID: 27533633 Free PMC article.
Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma.
Wang DY, Eroglu Z, Ozgun A, Leger PD, Zhao S, Ye F, Luke JJ, Joseph RW, Haq R, Ott PA, Hodi FS, Sosman JA, Johnson DB, Buchbinder EI. Wang DY, et al. Among authors: johnson db. Cancer Immunol Res. 2017 May;5(5):357-362. doi: 10.1158/2326-6066.CIR-16-0287. Epub 2017 Apr 10. Cancer Immunol Res. 2017. PMID: 28396509 Free PMC article.
Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection.
Tio M, Rai R, Ezeoke OM, McQuade JL, Zimmer L, Khoo C, Park JJ, Spain L, Turajlic S, Ardolino L, Yip D, Goldinger SM, Cohen JV, Millward M, Atkinson V, Kane AY, Ascierto PA, Garbe C, Gutzmer R, Johnson DB, Rizvi HA, Joshua AM, Hellmann MD, Long GV, Menzies AM. Tio M, et al. Among authors: johnson db. Eur J Cancer. 2018 Nov;104:137-144. doi: 10.1016/j.ejca.2018.09.017. Epub 2018 Oct 20. Eur J Cancer. 2018. PMID: 30347289 Free PMC article.
679 results